Cantor Fitzgerald Maintains a 'Buy' on DHT Holdings (DHT); Continues To Shore Up Balance Sheet, Keeps Dividend
Tweet Send to a FriendGet Alerts DHT Hot Sheet
Price: $4.71 +3.97%
Rating Summary:
3 Buy, 1 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
3 Buy, 1 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade DHT Now!
Cantor Fitzgerald maintains a 'Buy' on DHT Holdings (NYSE: DHT) price target of $2.50.
Cantor analyst said, "The company prepaid $18 million under its credit facility and expects to prepay another $12 million in 1Q:11 in order to remain in compliance with its loan to value covenant. As such, the next scheduled payment under this facility is 3Q:14. With $43 million of cash on the balance sheet at the end of 2011 and our positive cash flow for expectations 2012 and 2013, we suggest DHT has ample liquidity."
For an analyst ratings summary and ratings history on DHT Holdings click here. For more ratings news on DHT Holdings click here.
Shares of DHT Holdings closed at $0.81 yesterday, with a 52 week range of $0.66-$5.15.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Cantor analyst said, "The company prepaid $18 million under its credit facility and expects to prepay another $12 million in 1Q:11 in order to remain in compliance with its loan to value covenant. As such, the next scheduled payment under this facility is 3Q:14. With $43 million of cash on the balance sheet at the end of 2011 and our positive cash flow for expectations 2012 and 2013, we suggest DHT has ample liquidity."
For an analyst ratings summary and ratings history on DHT Holdings click here. For more ratings news on DHT Holdings click here.
Shares of DHT Holdings closed at $0.81 yesterday, with a 52 week range of $0.66-$5.15.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals (CBST) to Hold
- UPDATE: Sterne Agee Downgrades Beazer Homes (BZH) to Neutral
- Goldman Sachs Upgrades Abbott Labs (ABT) to Buy
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Cantor Fitzgerald, DividendLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

